Key result
Food-derived RAS-blocking peptides may improve insulin resistance and glucose intolerance in metabolic syndrome.
Answers are grounded in this paper and cite their sources.
In addition to the regulation of blood pressure, the renin-angiotensin system (RAS) also plays a key role in the onset and development of insulin resistance, which is central to metabolic syndrome (MetS). Due to the interplay between RAS and insulin resistance, antihypertensive compounds may exert beneficial effects in the management of MetS. Food-derived bioactive peptides with RAS blocking properties can potentially improve adipose tissue dysfunction, glucose intolerance, and insulin resistance involved in the pathogenesis of MetS. This review discusses the pathophysiology of hypertension and the association between RAS and pathogenesis of the MetS. The effects of bioactive peptides with RAS modulating effects on other components of the MetS are discussed. While the in vivo reports on the effectiveness of antihypertensive peptides against MetS are encouraging, the exact mechanism by which these peptides infer their effects on glucose and lipid handling is mostly unknown. Therefore, careful design of experiments along with standardized physiological models to study the effect of antihypertensive peptides on insulin resistance and obesity could help to clarify this relationship.
No takes yet. Share an insight, caveat, or question.
Forough Jahandideh (2020) conducted a review in Metabolic syndrome and hypertension. Food-derived bioactive antihypertensive peptides was evaluated on Adipose tissue dysfunction, glucose intolerance, and insulin resistance in metabolic syndrome. Food-derived antihypertensive peptides with RAS-blocking properties may improve insulin resistance and glucose intolerance in metabolic syndrome, though exact mechanisms remain largely unknown.
Synapse has enriched 10 related papers. Consider them for comparative context: